Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Our study aimed to assess the statistical relationship between the use of chloroquine phosphate or hydroxychloroquine plus azithromycin (CQ/HCQ + AZ) and virological recovery, disease worsening, and death among out- and inpatients with COVID-19 in Burkina Faso.
METHODS AND DESIGNS: This was a retrospective observational study that compared outcomes in terms of time to recovery, worsening, and death in patients who received CQ/HCQ + AZ and those who did not using a multivariable Cox or Poisson model before and after propensity matching.
RESULTS: Of the 863 patients included in the study, about 50% (432/863) were home-based follow-up patients and 50% were inpatients. Of these, 83.3% (746/863) received at least 1 dose of CQ/HCQ + AZ and 13.7% (118/863) did not. There were no significant differences in associated time to recovery for patients receiving any CQ/HCQ + AZ (adjusted HR 1.44; 95% CI 0.76-2.71). Similarly, there was no significant association between CQ/HCQ + AZ use and worsening (adjusted IRR 0.80; 95% CI 0.50-1.50). However, compared with the untreated group, the treated group had a lower risk of death (adjusted HR 0.20; 95% CI 0.10-0.44).
CONCLUSIONS: The study provided valuable additional information on the use of CQ/HCQ in patients with COVID-19 and did not show any harmful outcomes of CQ/HCQ + AZ treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 118(2022) vom: 15. Mai, Seite 224-229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rouamba, Toussaint [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 28.04.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2022.02.034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337592667 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337592667 | ||
| 003 | DE-627 | ||
| 005 | 20231225234755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2022.02.034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337592667 | ||
| 035 | |a (NLM)35227869 | ||
| 035 | |a (PII)S1201-9712(22)00111-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rouamba, Toussaint |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Our study aimed to assess the statistical relationship between the use of chloroquine phosphate or hydroxychloroquine plus azithromycin (CQ/HCQ + AZ) and virological recovery, disease worsening, and death among out- and inpatients with COVID-19 in Burkina Faso | ||
| 520 | |a METHODS AND DESIGNS: This was a retrospective observational study that compared outcomes in terms of time to recovery, worsening, and death in patients who received CQ/HCQ + AZ and those who did not using a multivariable Cox or Poisson model before and after propensity matching | ||
| 520 | |a RESULTS: Of the 863 patients included in the study, about 50% (432/863) were home-based follow-up patients and 50% were inpatients. Of these, 83.3% (746/863) received at least 1 dose of CQ/HCQ + AZ and 13.7% (118/863) did not. There were no significant differences in associated time to recovery for patients receiving any CQ/HCQ + AZ (adjusted HR 1.44; 95% CI 0.76-2.71). Similarly, there was no significant association between CQ/HCQ + AZ use and worsening (adjusted IRR 0.80; 95% CI 0.50-1.50). However, compared with the untreated group, the treated group had a lower risk of death (adjusted HR 0.20; 95% CI 0.10-0.44) | ||
| 520 | |a CONCLUSIONS: The study provided valuable additional information on the use of CQ/HCQ in patients with COVID-19 and did not show any harmful outcomes of CQ/HCQ + AZ treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Aggravation | |
| 650 | 4 | |a Burkina Faso | |
| 650 | 4 | |a Fatality | |
| 650 | 4 | |a SRAS-CoV-2 | |
| 650 | 4 | |a Viral clearance | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 700 | 1 | |a Ouédraogo, Esperance |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Houreratou |e verfasserin |4 aut | |
| 700 | 1 | |a Yaméogo, Nobila Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Sondo, Apoline |e verfasserin |4 aut | |
| 700 | 1 | |a Boly, Rainatou |e verfasserin |4 aut | |
| 700 | 1 | |a Zoungrana, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Ouédraogo, Abdoul Risgou |e verfasserin |4 aut | |
| 700 | 1 | |a Tahita, Marc Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Poda, Armel |e verfasserin |4 aut | |
| 700 | 1 | |a Diendéré, Arnaud Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Ouedraogo, Abdoul-Salam |e verfasserin |4 aut | |
| 700 | 1 | |a Valea, Innocent |e verfasserin |4 aut | |
| 700 | 1 | |a Traoré, Isidore |e verfasserin |4 aut | |
| 700 | 1 | |a Tarnagda, Zekiba |e verfasserin |4 aut | |
| 700 | 1 | |a Drabo, Maxime K |e verfasserin |4 aut | |
| 700 | 1 | |a Tinto, Halidou |e verfasserin |4 aut | |
| 700 | 0 | |a CHLORAZ study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 118(2022) vom: 15. Mai, Seite 224-229 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2022 |g day:15 |g month:05 |g pages:224-229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2022.02.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2022 |b 15 |c 05 |h 224-229 | ||